Ranibizumab + Aflibercept
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Visual Impairment Due to Diabetic Macular Edema
Conditions
Visual Impairment Due to Diabetic Macular Edema
Trial Timeline
Oct 1, 2015 → Oct 1, 2016
NCT ID
NCT02258009About Ranibizumab + Aflibercept
Ranibizumab + Aflibercept is a approved stage product being developed by Novartis for Visual Impairment Due to Diabetic Macular Edema. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02258009. Target conditions include Visual Impairment Due to Diabetic Macular Edema.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02878681 | Approved | Withdrawn |
| NCT02258009 | Approved | Withdrawn |
| NCT01958918 | Approved | Completed |
Competing Products
13 competing products in Visual Impairment Due to Diabetic Macular Edema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| Blink® Tears eye drops + Investigational lipid eye drops | Johnson & Johnson | Phase 1 | 33 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 77 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 77 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 23 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 30 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 20 |